Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 18
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Vitamin D Deficiency Is Associated with Advanced Liver Fibrosis and Impaired Fasting Glucose in Alcohol Use Disorder

  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Casado-Carbajo, Julia
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Bueno-Vélez, Marvin
  • García-Martin, Carmen
  • Muga, Roberto|||0000-0001-6301-431X
  • Fuster, Daniel|||0000-0003-1262-5860
Background: Vitamin D deficiency is a risk factor for liver disease, insulin resistance, and beta cell dysfunction. Individuals with alcohol use disorder (AUD) have many comorbidities, with a heavy burden of liver disease and metabolic complications, including type 2 diabetes mellitus (T2DM). Objective: We aimed to analyze the prevalence and associations of vitamin D deficiency in patients admitted for in-hospital treatment of AUD. Methods: A cross-sectional study was conducted in patients consecutively admitted for the treatment of AUD between January 2017 and October 2023. Sociodemographic data, substance use characteristics, and blood parameters were available at admission. Vitamin D status was assessed through the serum concentrations of 25-hydroxyvitamin D [25(OH)D] levels using a direct competitive chemiluminescent immunoassay method. Deficiency of vitamin D was defined as a concentration less than 20 ng/mL; impaired fasting glucose (IFG) was defined by fasting blood glucose.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Family farm succession and agroecology? A life-history approach to young farmers' sustainability strategies

  • Villan Delgado, Ana|||0000-0003-4172-4243
  • Villamayor-Tomas, Sergio|||0000-0002-5170-1718
  • Corbera, Esteve|||0000-0001-7970-4411
The generational renewal in family farms represents a pressing challenge for the sustainability of family farming, and agriculture more broadly. However, very few studies have investigated whether and how farm succession stimulates more sustainable farming. We apply an agroecology lens to farm sustainability and combine life-history research with other qualitative methods to describe three family farm succession pathways and investigate how these shape the farming strategies of young farmers in Castilla y León, Spain. We show how young farmers in blueprint succession pathways are inclined to continue with - and intensify - their parents' conventional farming strategies, assisted by farmer unions, public training, and policy subsidies. Agroecology appears instead after long disruptions in family succession as a cost-effective strategy to reinvigorate small and obsolete farms. Nonetheless, the agroecology transition is challenging, and disruptive successors have limited support from family, neighbors, farmer unions and subsidies. These findings problematize the idea that farm succession leads unequivocally to more sustainable farming, and suggest that generational renewal policies should broaden their compass to support disruptive succession processes and provide specific support for agroecological transitions.
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

An Exploratory Study on the Pathogenic Role of Faecal Extracellular Vesicles in Metabolic Dysfunction-Associated Steatotic Liver Disease Progression and in Drug-Induced Liver Injury

  • Ruiz-Malagón, Antonio J.
  • Herraiz-Vilela, Marina
  • Pinazo-Bandera, José
  • Toro-Ortiz, Juan Pedro
  • López-Gómez, Carlos
  • Ho-Plagaro, Ailec
  • Garrido-Sánchez, Lourdes
  • Robles-Díaz, María Mercedes
  • Taminiau, Bernard
  • Daube, Georges
  • Sanabria-Cabrera, Judith
  • Matilla-Cabello, Gonzalo
  • Lucena-González, María Isabel
  • Andrade-Bellido, Raúl Jesús
  • García-Fuentes, Eduardo
  • García-Cortés, Miren
  • Rodríguez-Díaz, Cristina
The role of extracellular vesicles secreted by the gut microbiota present in faeces (fEVs) is not well known in metabolic dysfunction- associated steatotic liver disease (MASLD) and idiosyncratic drug-induced liver injury (DILI). We identify the microbiome profiles of fEVs in these liver diseases, and analyse the effects of fEVs from MASLD, without (F ≤ 2) or with (F ≥ 3) significant liver fibrosis, and DILI patients on inflammation, steatosis and mitochondrial function. DILI patients showed a consistent pattern in fEVs, characterised by a decrease in Paraprevotella and an increase in AAP99, Acinetobacter, Actinobacillus, Aerococcus and Anaeroglobus . A higher presence of 16S rDNA was observed in plasma EVs from MASLD and DILI patients. HepG2 cells treated with DILI and MASLD F ≥ 3 fEVs increased TLR4 , TLR5 , IL6 and CASP3 expression, and accumulation of lipid droplets. DILI fEVs enhanced the hepatotoxic impact of diclofenac on the response to microbial components ( TLR4 , TLR5 ), inflammatory response ( IL1B , IL6 ), accumulation of lipid droplets and mitochondrial dysfunction ( OPA1 , DNM1L ). In conclusion, bacterial EVs enter the bloodstream and could modulate the immune response. DILI and MASLD F ≥ 3 fEVs are drivers of the pro-inflammatory response and hepatocyte steatosis. DILI fEVs have a distinct bacterial profile that enhances the hepatotoxic potential of diclofenac., Instituto de Salud Carlos III, Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía, Consejería de Salud, Junta de Andalucía, European Comission, Ministerio de Ciencia, Innovación y Universidades
Repisalud
Publicación Artículo científico (JournalArticle)

Aldosterone Induces Renal Fibrosis and Inflammatory M1-Macrophage Subtype via Mineralocorticoid Receptor in Rats

  • Martín-Fernández, Beatriz
  • Rubio-Navarro, Alfonso
  • Cortegano, Isabel
  • Ballesteros, Sandra
  • Alia, Mario
  • Cannata-Ortiz, Pablo
  • Olivares-Álvaro, Elena
  • Egido, Jesús
  • Andres, Belen de
  • Gaspar, Maria Luisa
  • de Las Heras, Natalia
  • Lahera, Vicente
  • Moreno, Juan Antonio
We aimed to evaluate macrophages heterogeneity and structural, functional and inflammatory alterations in rat kidney by aldosterone + salt administration. The effects of treatment with spironolactone on above parameters were also analyzed. Male Wistar rats received aldosterone (1 mgkg-1d-1) + 1% NaCl for 3 weeks. Half of the animals were treated with spironolactone (200 mg kg-1d-1). Systolic and diastolic blood pressures were elevated (p<0.05) in aldosterone + salt-treated rats. Relative kidney weight, collagen content, fibronectin, macrophage infiltrate, CTGF, Col I, MMP2, TNF-α, CD68, Arg2, and SGK-1 were increased (p<0.05) in aldosterone + salt-treated rats, being reduced by spironolactone (p<0.05). Increased iNOS and IFN-γ mRNA gene expression (M1 macrophage markers) was observed in aldosterone + salt rats, whereas no significant differences were observed in IL-10 and gene ArgI mRNA expression or ED2 protein content (M2 macrophage markers). All the observed changes were blocked with spironolactone treatment. Macrophage depletion with liposomal clodronate reduced macrophage influx and inflammatory M1 markers (INF-γ or iNOS), whereas interstitial fibrosis was only partially reduced after this intervention, in aldosterone plus salt-treated rats. In conclusion, aldosterone + salt administration mediates inflammatory M1 macrophage phenotype and increased fibrosis throughout mineralocorticoid receptors activation.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Fluorinated Zirconium-Based Metal-Organic Frameworks as Novel Sorbents to Improve the Efficacy of Hemodialysis Treatment

  • Guerrero, Fátima
  • Moscoso, Francisco G.
  • Silvestre-Albero, Joaquín
  • Martin-Malo, Alejandro
  • Carrillo-Carrión, Carolina
  • Silvestre-Albero, Joaquín|||/items/340b8128-2e1e-4869-8845-03b1802a1577
People with end-stage chronic kidney disease (CKD) require routine dialysis treatments to remove uremic toxins from the blood in order to minimize toxic symptoms. However, some hydrophobic toxins cannot be effectively removed using conventional hemodialysis techniques, especially when they are bound to plasma proteins. This work reports the first experimental evidence addressing this issue through the incorporation of perfluoroligands into a zirconium-based metal-organic framework, taking advantage of the favorable interactions between fluorine atoms and albumin proteins. The as-designed fluorinated NU-1000 particles (NU@F) demonstrate their capability to remove not only free hydrophobic uremic toxins, specifically p-cresyl sulfate (pCS) and indoxyl sulfate (IS), but also a large fraction of those bound to human serum albumin, notably without causing significant hypoalbuminemia. The NU@F particles incorporated into a cartridge also exhibit good performance under dynamic flow conditions, mimicking the real scenario of hemodialysis. Finally, the NU@F dialysis system is tested in a pooled sample from CKD patients, confirming the actual application potential of the developed prototype system.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Juan de Ribera y el padre jesuita Miguel Gobierno en la crisis de 1574

  • García Hernán, Enrique
Con autorización de la editorial para este capítulo., El presente libro es resultado del Proyecto de Investigación "San Juan de Ribera cuatrocientos años después: su vida, obra y afanes a la luz del siglo XXI", financiado sucesivamente por la Universidad CEU Cardenal Herrera (PRUCH17/08) y el Ministerio de Ciencia e Innovación (HAR2008/00883) a través de sendos Proyectos 1 + D, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Membrane Vesicles of Toxigenic Clostridioides difficile Affect the Metabolism of Liver HepG2 Cells

  • Caballano-Infantes, Estefanía
  • Ho-Plagaro, Ailec
  • López-Gómez, Carlos
  • Martín-Reyes, Flores
  • Rodríguez-Pacheco, Francisca
  • Taminiau, Bernard
  • Daube, Georges
  • Garrido-Sánchez, Lourdes
  • Alcaín-Martínez, Guillermo
  • Andrade, Raúl J.
  • García-Cortés, Miren
  • Lucena, M. Isabel
  • García-Fuentes, Eduardo
  • Rodríguez-Díaz, Cristina
Clostridioides difficile infection (CDI) appears to be associated with different liver diseases. C. difficile secretes membrane vesicles (MVs), which may be involved in the development of nonalcoholic fatty liver disease (NALFD) and drug-induced liver injury (DILI). In this study, we investigated the presence of C. difficile-derived MVs in patients with and without CDI, and analyzed their effects on pathways related to NAFLD and DILI in HepG2 cells. Fecal extracellular vesicles from CDI patients showed an increase of Clostridioides MVs. C. difficile-derived MVs that were internalized by HepG2 cells. Toxigenic C. difficile-derived MVs decreased mitochondrial membrane potential and increased intracellular ROS compared to non-toxigenic C. difficile-derived MVs. In addition, toxigenic C. difficile-derived MVs upregulated the expression of genes related to mitochondrial fission (FIS1 and DRP1), antioxidant status (GPX1), apoptosis (CASP3), glycolysis (HK2, PDK1, LDHA and PKM2) and β-oxidation (CPT1A), as well as anti- and pro-inflammatory genes (IL-6 and IL-10). However, non-toxigenic C. difficile-derived MVs did not produce changes in the expression of these genes, except for CPT1A, which was also increased. In conclusion, the metabolic and mitochondrial changes produced by MVs obtained from toxigenic C. difficile present in CDI feces are common pathophysiological features observed in the NAFLD spectrum and DILI., This work was supported in part by a grant from the Instituto de Salud Carlos III (Spain) (PI18/01652, PI19/00883 and PI21/01248), and from the Consejería de Economía, Conocimiento, Empresas y Universidad (Junta de Andalucía, Spain) (PI18-RT-3364 and UMA18-FEDERJA-194). This study has been co-funded by FEDER funds (“A way to make Europe”) (“Andalucía se mueve con Europa”). CRD is supported by a grant from the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de Junta de Andalucía (Spain) (DOC_01610). FMR is supported by a grant from the ISCIII (Spain) (FI19/00189). CLG is supported by a grant from the ISCIII (CP22/00050) (Spain). FRP is supported by the Miguel Servet program from the ISCIII (Spain) (CP18/00042). LGS is supported by the Nicolas Monardes program from the Consejería de Salud de Andalucía (Spain) (C-0028-2018). EGF is supported by the Nicolas Monardes program from the Consejería de Salud de Andalucía (Spain) (RC-0005-2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

  • Lucena, M. Isabel
  • Villanueva-Paz, M.
  • Álvarez-Álvarez, I.
  • Aithal, G. P.
  • Björnsson, E. S.
  • Cakan-Akdogan, G.
  • Cubero, Francisco Javier
  • Esteves, F.
  • Falcón-Pérez, Juan M.
  • Fromenty, B.
  • García-Ruiz, Carmen
  • Grove, J. I.
  • Konu, O.
  • Kranendonk, M.
  • Kullak-Ublick, G. A.
  • Miranda, Joana
  • Remesal-Doblado, A.
  • Sancho-Bru, P.
  • Nelson, L.
  • Andrade, Raúl J.
  • Daly, A. K.
  • Fernández-Checa, José C.
In the current article the aims for a constructive way forward in Drug-Induced Liver Injury (DILI) are to highlight the most important priorities in research and clinical science, therefore supporting a more informed, focused, and better funded future for European DILI research. This Roadmap aims to identify key challenges, define a shared vision across all stakeholders for the opportunities to overcome these challenges and propose a high-quality research program to achieve progress on the prediction, prevention, diagnosis and management of this condition and impact on healthcare practice in the field of DILI. This will involve 1. Creation of a database encompassing optimised case report form for prospectively identified DILI cases with well-characterised controls with competing diagnoses, biological samples, and imaging data; 2. Establishing of preclinical models to improve the assessment and prediction of hepatotoxicity in humans to guide future drug safety testing; 3. Emphasis on implementation science and 4. Enhanced collaboration between drug-developers, clinicians and regulatory scientists. This proposed operational framework will advance DILI research and may bring together basic, applied, translational and clinical research in DILI., The present study has been supported by grants from Instituto de Salud Carlos III (ISCIII) (contract numbers: PID2022–140169OB-C21; PI21/01248; PI19/00883) and from Consejería de Salud de Andalucía (contract number: PEMP-0127–2020, Spain), cofounded by the European Union. This research was funded by HORIZON-HLTH-2022-STAYHLTH-02, grant number 101095679. Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. MK was partially supported by Grant UID/BIM/0009/2020 of the Portuguese Fundação para a Ciência e a Tecnologia (FCT). MVP and IAA hold Sara Borrell research contracts from ISCIII (CD21/00198 and CD20/00083, respectively). This research was supported by CIBERehd – Consorcio Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. JIG and GPA are supported by NIHR Nottingham Biomedical Research Centre [NIHR203310]. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. This publication is based upon work from COST Action “CA17112—Prospective European Drug-Induced Liver Injury Network” supported by COST (European Cooperation in Science and Technology); www.cost.eu., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Long-Term Outcomes of Patients With Cocaine Use Disorder, A 18-years Addiction Cohort Study

  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Zuluaga Cruz, Andrea Paola|||0000-0002-3003-4856
  • Fuster, Daniel|||0000-0003-1262-5860
  • Papaseit, Esther|||0000-0003-2620-4274
  • Galan, Sara
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Muga, Roberto|||0000-0001-6301-431X
Objective: Cocaine Use Disorder (CUD) has been associated with multiple complications and premature death. The purpose of the present study was to analyze the relationship between baseline medical comorbidity and long-term medical outcomes (i.e., hospitalization, death) in a cohort of patients primarily admitted for detoxification. In addition, we aimed to analyze cause-specific mortality. Methods: longitudinal study in CUD patients admitted for detoxification between 2001 and 2018. Substance use characteristics, laboratory parameters and medical comorbidity by VACS Index were assessed at admission. Follow-up and health-related outcomes were ascertained through visits and e-health records. Kaplan-Meier and Cox regression models were used to analyze survival and predictors of hospitalization and death. Results: 175 patients (77.7% men) were included. Age at admission was 35 years [IQR: 30-41 years], 59.4% of the patients being intranasal users, 33.5% injectors, and 7.1% smokers. Almost 23% of patients had concomitant alcohol use disorder, 39% were cannabis users and 9% opiate users. The median VACS Index score on admission was 10 points [IQR: 0-22]. After 12 years [IQR: 8.6-15 years] of follow-up there were 1,292 (80.7%) ED admissions and 308 (19.3%) hospitalizations. The incidence rate of ED admission and hospitalization was 18.6 × 100 p-y (95% CI: 15.8-21.8 × 100 p-y). Mortality rate was 1.4 × 100 p-y (95% CI: 0.9-2.0 × 100 p-y) and, baseline comorbidity predicted hospitalization and mortality: those with VACS Index.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use

  • Fuster, Daniel|||0000-0003-1262-5860
  • García Calvo, Xavier|||0000-0001-8165-8717
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Bolao, Ferran|||0000-0002-9104-6615
  • Muga, Roberto|||0000-0001-6301-431X
Hepatitis C virus (HCV) infection and unhealthy alcohol use are major drivers of the burden of liver disease worldwide and commonly co-occur. Assessment of underlying liver damage is a cornerstone of the clinical care of patients with chronic HCV infection and/or unhealthy alcohol use because many of them are diagnosed at advanced stages of disease. Early diagnosis of liver disease before decompensated liver cirrhosis becomes established is essential for treatment with direct acting antivirals and/or abstinence from alcohol consumption, which are the main therapeutic approaches for clinical management. In this review, we discuss current knowledge around the use of non-invasive methods to assess liver disease, such as abdominal ultrasound, controlled attenuation parameter, transient elastography, magnetic resonance imaging, and indices based on serum markers of liver injury.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prevalence and associations of metabolic syndrome in patients with alcohol use disorder

  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Bolao, Ferran|||0000-0002-9104-6615
  • Cachón-Suárez, Isabel
  • Garcia-Martín, Carme
  • Short, Antoni
  • Bataller, Ramon|||0000-0002-1119-7799
  • Muga, Roberto|||0000-0001-6301-431X
Excessive alcohol consumption has been associated with different components of the metabolic syndrome (MetS) such as arterial hypertension, dyslipidemia, type 2 diabetes or obesity. We aimed to analyze the prevalence and associations of MetS in patients with Alcohol Use Disorder (AUD). Cross-sectional study in heavy drinkers admitted for the treatment of AUD between 2013 and 2017. Medical comorbidity, anthropometric data, alcohol use and biological parameters were obtained. MetS was established according to the harmonized definition. A total of 728 patients (22% women) were included; median age was 47 years (IQR: 40-53.5), median alcohol consumption was 160 g/day (IQR: 115-240) and prevalence of MetS was 13.9%. The multivariate analysis showed a significant dose-response effect of estimated glomerular filtration (eGFR) and MetS: relative to patients with eGFR.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry

  • Stephens, Camilla|||0000-0002-0796-9610
  • Robles Díaz, Mercedes|||0000-0002-2365-2787
  • Medina-Cáliz, Inmaculada|||0000-0003-0471-6658
  • Garcia-Cortes, Miren|||0000-0003-0410-8273
  • Ortega-Alonso, Aida|||0000-0002-8999-4093
  • Sanabria-Cabrera, Judith|||0000-0002-7769-7008
  • Gonzalez-Jimenez, Andrés
  • Alvarez-Alvarez, Ismael
  • Slim, Mahmoud|||0000-0003-2455-1432
  • Jimenez-Perez, Miguel
  • Gonzalez-Grande, Rocio
  • Fernández, M.Carmen
  • Casado, Marta
  • Soriano, German|||0000-0002-9267-6811
  • Roman, Eva|||0000-0001-9084-8555
  • Hallal, Hacibe
  • Romero-Gómez, Manuel|||0000-0001-8494-8947
  • Castiella, Agustin
  • Conde, Isabel|||0000-0001-7863-2233
  • Prieto, Martin
  • Moreno-Planas, Jose Maria
  • Giraldez, Alvaro
  • Moreno-Sanfiel, J.Miguel
  • Kaplowitz, Neil
  • Lucena, M. Isabel|||0000-0001-9586-4896
  • Andrade, Raúl J.
  • Cortés, M.G.
  • Pinazo, Jose
  • García Muñoz, B.
  • Alcántara, Ramiro
  • Hernández, Andrés
  • Escaño, M.D.García
  • del Campo, E.
  • González-Jiménez, A.
  • Sanjuán Jiménez, Rocío
  • Cueto, Alejandro
  • Bonilla, Elvira
  • Di Zeo, D.
  • Niu, H.
  • Villanueva-Paz, Marina|||0000-0003-4728-201X
  • Papineau, A.
  • Pérez Hernández, Manuel José
  • González-Grande, Rocío|||0000-0002-7691-5755
  • López Ortega, S.
  • Santaella, I.
  • Ocaña, A.
  • Palomino, P.
  • Fernández, Maria Carmen
  • Peláez, Gloria
  • Porcel, A.
  • Casado, M.
  • González Sánchez, Mara
  • Millán-Domínguez, R.
  • Fombuena, Blanca
  • Gallego, Rocío
  • Ampuero, Javier|||0000-0002-8332-2122
  • Del Campo, José Antonio
  • Calle-Sanz, R.
  • Rojas, Lourdes
  • Rojas, Ángela|||0000-0003-0853-4800
  • Gil Gómez, Alexandra
  • Vilar, Eduardo
  • Guarner, Carlos|||0000-0001-5957-9481
  • Quijada-Manuitt, María Ángeles|||0000-0002-9624-0177
  • Antonijoan Arbós, Rosa Ma|||0000-0002-7099-5125
  • Sánchez Delgado, Jordi|||0000-0002-5217-6492
  • Vergara Gómez, Mariano
  • Hallal, H.
  • García Oltra, Ester
  • Titos Arcos, J.C.
  • Pérez Martínez, Alfonso
  • Sánchez Cobarro, C.
  • Egea Caparrós, J.M.
  • Zapata, Eva María
  • Arenas, Juan Ignacio
  • Gómez García, Alexandra
  • Esandi, F.J.
  • Blanco, Sonia
  • Martínez Odriozola, Pedro
  • Crespo García, Javier|||0000-0001-8248-0172
  • Iruzubieta, Paula|||0000-0001-9476-1801
  • Cabezas González, Joaquín|||0000-0003-0012-484X
  • Giráldez Gallego, Álvaro
  • Rodríguez Seguel, Elisa
  • Cuaresma, María
  • González-Gallego, Javier|||0000-0002-4386-9342
  • Jorquera, Francisco|||0000-0002-1799-2881
  • Sánchez Campos, S.
  • Otazua, Pedro
  • de Juan Gómez, A.
  • Salmerón, Javier
  • Gila, Ana
  • Quiles, Rosa
  • González, José Manuel
  • Lorenzo, Sara
  • Prieto, Martín
  • Conde Amiel, I.
  • Berenguer, Marina|||0000-0001-9246-4264
  • García-Eliz, María
  • Primo, Joaquín
  • Molés, José Ramón
  • Garayoa, Ana
  • Carrascosa, Miguel
  • Gómez Domínguez, Elena
  • Cuevas, L.
  • Farré Albaladejo, Magí|||0000-0001-8338-7543
  • Montané Esteva, Eva|||0000-0002-1691-7652
  • Barriocanal, Ana María|||0000-0002-4159-519X
  • Arellano, Ana Lucía|||0000-0001-8601-3504
  • Sanz, Yolanda
  • Morillas Cunill, Rosa Ma|||0000-0001-9117-5049
  • Sala, Margarita
  • Masnou Ridaura, H.
  • Bruguera, Miquel
  • Ginès, Pere|||0000-0003-4657-4504
  • Lens, Sabela|||0000-0003-4900-411X
  • Mariño, Zoe|||0000-0001-6321-9534
  • Hernández Guerra, Manuel
  • Moreno Sanfiel, J.M.
  • Fernández del Campo, C.Boada
  • Tejedor, Martián
  • González Ferrer, Ruth
  • Fernández, Conrado
  • Fernández Gil, Marta
  • Montero, José Luís
  • de la Mata, Manuel
  • Fuentes Olmo, Javier|||0000-0001-8637-510X
  • Fernández Bonilla, E.M.
  • Moreno, Julián M.
  • Martínez-Ródenas, Ponciano
  • Gómez Garrido, M.
  • Oliva, C.
  • Rendón, Paloma|||0000-0002-6521-3766
  • García Samaniego, Javier
  • Madejón, Antonio
  • Calleja, Jose Luis|||0000-0002-2265-6591
  • Martínez Porras, J.L.
  • Cabriada, José Luis|||0000-0002-3068-5659
  • Pérez-Moreno, José Manuel
  • Lara, Carmen
Background & Aims: Prospective drug-induced liver injury (DILI) registries are important sources of information on idiosyncratic DILI. We aimed to present a comprehensive analysis of 843 patients with DILI enrolled into the Spanish DILI Registry over a 20-year time period. Methods: Cases were identified, diagnosed and followed prospectively. Clinical features, drug information and outcome data were collected. Results: A total of 843 patients, with a mean age of 54 years (48% females), were enrolled up to 2018. Hepatocellular injury was associated with younger age (adjusted odds ratio [aOR] per year 0.983; 95% CI 0.974-0.991) and lower platelet count (aOR per unit 0.996; 95% CI 0.994-0.998). Anti-infectives were the most common causative drug class (40%). Liver-related mortality was more frequent in patients with hepatocellular damage aged ≥65 years (p = 0.0083) and in patients with underlying liver disease (p = 0.0221). Independent predictors of liver-related death/transplantation included nR-based hepatocellular injury, female sex, higher onset aspartate aminotransferase (AST) and bilirubin values. nR-based hepatocellular injury was not associated with 6-month overall mortality, for which comorbidity burden played a more important role. The prognostic capacity of Hy's law varied between causative agents. Empirical therapy (corticosteroids, ursodeoxycholic acid and MARS) was prescribed to 20% of patients. Drug-induced autoimmune hepatitis patients (26 cases) were mainly females (62%) with hepatocellular damage (92%), who more frequently received immunosuppressive therapy (58%). Conclusions: AST elevation at onset is a strong predictor of poor outcome and should be routinely assessed in DILI evaluation. Mortality is higher in older patients with hepatocellular damage and patients with underlying hepatic conditions. The Spanish DILI Registry is a valuable tool in the identification of causative drugs, clinical signatures and prognostic risk factors in DILI and can aid physicians in DILI characterisation and management. Lay summary: Clinical information on drug-induced liver injury (DILI) collected from enrolled patients in the Spanish DILI Registry can guide physicians in the decision-making process. We have found that older patients with hepatocellular type liver injury and patients with additional liver conditions are at a higher risk of mortality. The type of liver injury, patient sex and analytical values of aspartate aminotransferase and total bilirubin can also help predict clinical outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide

  • Fernandez-Perez, María P.
  • Perez-Navarro, Enrique|||0000-0003-1091-8926
  • Alonso-Gordoa, Teresa|||0000-0002-8966-7236
  • Conteduca, Vincenza|||0000-0002-6921-714X
  • Font, Albert|||0000-0003-3908-1111
  • Vázquez-Estévez, Sergio
  • González-del-Alba, Aránzazu|||0000-0001-6570-009X
  • Wetterskog, Daniel
  • Antonarakis, Emmanuel S.
  • Mellado, Begoña|||0000-0002-8088-5966
  • Fernández Calvo, Ovidio|||0000-0001-5283-9754
  • Mendez Vidal, María José|||0000-0002-7460-1859
  • Climent, Miguel Ángel|||0000-0001-7523-0212
  • Durán, Ignacio|||0000-0001-8571-7163
  • Gallardo Díaz, Enrique|||0000-0002-1375-3488
  • Rodríguez Sánchez, Ángel
  • Santander, Carmen
  • Sáez, Maria I.
  • Puente, J.|||0000-0002-6910-1331
  • Tudela, Julian
  • Martínez, Alberto
  • López-Andreo, María José|||0000-0002-7015-8132
  • Padilla, José
  • Lozano, Rebeca
  • Hervas, David|||0000-0003-0635-4961
  • Luo, Jun
  • De Giorgi, Ugo|||0000-0001-7520-2908
  • Castellano, Daniel|||0000-0002-9106-0687
  • Attard, Gerhardt
  • Grande, Enrique|||0000-0002-0134-4732
  • Gonzalez-Billalabeitia, Enrique|||0000-0003-3143-3143
There is a considerable need to incorporate biomarkers of resistance to new antiandrogen agents in the management of castration-resistant prostate cancer (CRPC). We conducted a phase II trial of enzalutamide in first-line chemo-naïve asymptomatic or minimally symptomatic mCRPC and analyzed the prognostic value of TMPRSS2-ERG and other biomarkers, including circulating tumor cells (CTCs), androgen receptor splice variant (AR-V7) in CTCs and plasma Androgen Receptor copy number gain (AR-gain). These biomarkers were correlated with treatment response and survival outcomes and developed a clinical-molecular prognostic model using penalized cox-proportional hazard model. This model was validated in an independent cohort. Ninety-eight patients were included. TMPRSS2-ERG fusion gene was detected in 32 patients with no differences observed in efficacy outcomes. CTC detection was associated with worse outcome and AR-V7 in CTCs was associated with increased rate of progression as best response. Plasma AR gain was strongly associated with an adverse outcome, with worse median prostate specific antigen (PSA)-PFS (4.2 vs. 14.7 m; p < 0.0001), rad-PFS (4.5 vs. 27.6 m; p < 0.0001), and OS (12.7 vs. 38.1 m; p < 0.0001). The clinical prognostic model developed in PREVAIL was validated (C-Index 0.70) and the addition of plasma AR (C-Index 0.79; p < 0.001) increased its prognostic ability. We generated a parsimonious model including alkaline phosphatase (ALP); PSA and AR gain (C-index 0.78) that was validated in an independent cohort. TMPRSS2-ERG detection did not correlate with differential activity of enzalutamide in first-line mCRPC. However, we observed that CTCs and plasma AR gain were the most relevant biomarkers.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Cytotoxic NK cells phenotype and activated lymphocytes are the main characteristics of patients with alcohol-associated liver disease

  • Zurera Egea, Coral|||0000-0003-1712-5216
  • Teniente Serra, Aina|||0000-0003-3440-804X
  • Fuster, Daniel|||0000-0003-1262-5860
  • Martínez Cáceres, Eva María|||0000-0002-6762-8025
  • Muga, Roberto|||0000-0001-6301-431X
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
T cells, natural killer (NK) and NKT cells have opposing actions in the development of alcohol-associated liver fibrosis. We aimed to evaluate the phenotype of NK cells, NKT cells and activated T cells in patients with alcohol use disorder (AUD) according to the presence of advanced liver fibrosis (ALF). Totally, 79 patients (51-years, 71% males) were admitted to treatment of AUD. ALF was defined as FIB4-score > 2.67. Immunophenotyping of NK cells (CD3CD56CD16, CD3CD56CD16, CD3CD56CD16), NKT-like (CD3CD56), and the activation status of CD4, CD8 and regulatory T cells (Tregs) were evaluated according to the HLA-DR expression. Patients had an AUD duration of 18 ± 11 years with a daily alcohol consumption of 155 ± 77 gr/day prior to hospital admission. The values of absolute cells were 2 ± 0.9 cells/L for total lymphocytes, 1054 ± 501 cells/µL for CD4, 540 ± 335 cells/µL for CD8, 49.3 ± 24.8 cells/µL for Tregs, 150.3 ± 97.5 cells/µL for NK cells and 69.8 ± 78.3 cells/µL for NKT-like. The percentage of total NK cells (11.3 ± 5.5% vs. 7 ± 4.3%, p < 0.01), CD3CD56CD16 regarding total lymphocytes (9.7 ± 5.1% vs. 5.8 ± 3.9%, p < 0.01), activated CD4 cells (5.2 ± 3.2% vs. 3.9 ± 3%, p = 0.04) and activated CD8 cells (15.7 ± 9.1% vs. 12.2 ± 9%, p = 0.05) were significantly higher in patients with ALF. The percentage of CD3CD56CD16 regarding NK cells (5.1 ± 3.4% vs. 7.6 ± 6.2%, p = 0.03) was significantly lower in patients with ALF. Activated Tregs (39.9 ± 11.5 vs. 32.4 ± 9.2, p = 0.06) showed a tendency to be higher in patients with ALF. The proportion of activated CD4 cells (r = 0.40, p < 0.01) and activated CD8 cells (r = 0.51, p < 0.01) was correlated with the proportion of NKT-like in patients without ALF. Patients with ALF presented an increased NK cytotoxic phenotype and activated T cells concomitant with a decreased NK cytokine-secreting phenotype.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries

  • Medina-Cáliz, Inmaculada|||0000-0003-0471-6658
  • Sanabria-Cabrera, Judith|||0000-0002-7769-7008
  • Villanueva-Paz, Marina|||0000-0003-4728-201X
  • Aukštikalnė, Lauryna
  • Stephens, Camilla|||0000-0002-0796-9610
  • Robles Díaz, Mercedes|||0000-0002-2365-2787
  • Pinazo-Bandera, José M.
  • García-Cortes, Miren
  • Conde, Isabel|||0000-0001-7863-2233
  • Soriano, German|||0000-0002-9267-6811
  • Bessone, Fernando
  • Hernandez, Nelia
  • Nunes, Vinicius
  • Paraná, Raymundo
  • Lucena, M. Isabel|||0000-0001-9586-4896
  • Andrade, Raúl J.
  • Niu, Hao
  • Alvarez-Alvarez, Ismael
Idiosyncratic drug-induced liver injury (DILI) associated with drug reactions with eosinophilia and systemic symptoms (DRESS) is poorly characterized among patients of Western countries. We aimed to comprehensively assess the clinical characteristics, outcomes, and causative agents in a prospective, well-vetted cohort of DILI patients with DRESS (DILI-DRESS). We identified 53 DILI-DRESS cases from the Spanish DILI Registry and the Latin American DILI Network. For comparison purposes, we defined a group of DILI patients (n = 881). DILI-DRESS cases were younger (47 vs. 53 years, respectively; p = 0.042) and presented more frequently with cholestatic/mixed damage (p = 0.018). Most DILI-DRESS patients showed moderate liver injury, 13% developed severe damage, and only one patient (with hepatocellular injury due to anti-tuberculosis drugs) progressed to acute liver failure and died. DILI-DRESS cases showed a distinctive causative drug pattern compared to DILI cases. The most frequent drugs were carbamazepine (13%), anti-tuberculosis drugs (13%), amoxicillin-clavulanate (11%), and allopurinol and lamotrigine (7.6% each). Among all cases of DILI due to allopurinol and lamotrigine, 67% presented with a DILI-DRESS phenotype, respectively. Higher total bilirubin (TBL) levels at DILI recognition (odds ratio [OR] 1.23; 95% confidence interval [CI] 1.04-1.45) and absence of eosinophilia (OR 8.77; 95% CI 1.11-69.20) increased the risk for developing a severe-fatal injury in DILI-DRESS patients. DILI-DRESS patients have a more frequent cholestasis/mixed pattern of injury at presentation, with antiepileptics as distinctive causative drug class. Most of the lamotrigine and allopurinol cases present with this phenotype. Higher TBL levels and absence of eosinophilia at DILI recognition are markers of poor outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Clinical features of individuals with laboratory values suggestive of advanced liver fibrosis when first treated for alcohol use disorder

  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Fuster, Daniel|||0000-0003-1262-5860
  • Blanes, Rafael
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Miquel, Laia
  • Torrens, Marta
  • Rubio, Gabriel
  • Bolao, Ferran|||0000-0002-9104-6615
  • Liangpunsakul, Suthat|||0000-0002-6504-8123
  • Abellí-Deulofeu, Enric
  • Rodríguez de Fonseca, Fernando|||0000-0002-4516-5795
  • Muga, Roberto|||0000-0001-6301-431X
Background: Effective screening for alcohol-associated liver disease is relevant in the context of chronic, excessive alcohol consumption. Patients with alcohol-associated liver disease are often not diagnosed until their liver disease is decompensated. We analyzed the prevalence and associations of Fibrosis-4 index (FIB-4) values suggestive of advanced liver fibrosis in patients referred for their first treatment of alcohol use disorder (AUD). Methods: We conducted a cross-sectional, multicenter study of noncirrhotic individu-als referred for their first AUD treatment between March 2013 and April 2021. We obtained sociodemographic data, substance use characteristics, and blood samples at admission. We considered a FIB-4 value ≥2.67 suggestive of advanced liver fibrosis and used logistic regression analyses to identify features associated with this value. Results: We included 604 patients (67% male), with a median age at admission of 48 years [IQR: 41-56 years]. The median duration of regular alcohol consumption was 21 years [IQR: 18-30 years] and the median alcohol consumption was 105 standard drink units (SDU)/week [IQR: 63-160 SDU/week]. A FIB-4 value ≥ 2.67 was present in 19.3% of cases. These patients reported more frequent binge drinking (75.4% vs. 66%, p= 0.05) than those with FIB-4 values below 2.67. In multivariate analysis, a history of binge drinking (OR 1.9, 95% CI, 1.05-3.47), anemia (OR 2.95, 95% CI, 1.42-6.11), leukopenia (OR 7.46, 95% CI, 2.07-26.8), and total serum bilirubin.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Treatment of alcohol use disorder in patients with alcohol-associated liver disease, Innovative approaches and a call to action

  • Haque, Lamia Y.|||0000-0002-6650-0978
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Muga, Roberto|||0000-0001-6301-431X
  • Fuster, Daniel|||0000-0003-1262-5860
Alcohol-associated liver disease is currently the leading cause of liver transplantation and liver deaths both in Europe and the United States. Efficacious treatments exist for alcohol use disorder, but they are seldomly prescribed for patients who need them. Besides, the presence of liver cirrhosis can complicate pharmacological treatment choices. In this review, we discuss established and innovative treatment strategies to treat unhealthy alcohol use in patients with alcohol-associated liver disease. We also describe the experience of our own institutions, Hospital Universitari Germans Trias i Pujol in Badalona (Spain) and Yale-New Haven Health and Yale Medicine (Connecticut. United States of America).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Markers of monocyte activation, inflammation, and microbial translocation are associated with liver fibrosis in alcohol use disorder

  • Fuster, Daniel|||0000-0003-1262-5860
  • García Calvo, Xavier|||0000-0001-8165-8717
  • Farré, Oriol
  • Zuluaga Blanco, Yenny Paola|||0000-0002-0247-0351
  • Bolao, Ferran|||0000-0002-9104-6615
  • Leis, Alba|||0000-0003-3928-7849
  • Hernandez Rubio, Anna|||0000-0001-8612-7827
  • Rivas, Inmaculada|||0000-0003-2633-5530
  • Muga, Roberto|||0000-0001-6301-431X
Background: The association between markers of inflammation (interleukin (IL)-6 and IL-10), monocyte activation (sCD163 and sCD14), and microbial translocation (lipopolysaccharide (LPS) and LPS binding protein) and liver fibrosis in patients with alcohol use disorder (AUD) and no overt liver disease is not well established. Methods: We studied patients admitted for treatment of AUD at two hospitals in Barcelona. Advanced liver fibrosis (ALF) was defined as FIB-4.